touchIMMUNOLOGY caught up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) to talk about the results for the phase 2 study investigating the oral transglutaminase 2 inhibitor, ZED1227, in patients with celiac disease.
His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at UEG Week Virtual, 3-5 Oct 2021.
Questions
- What is ZED1227 and what is the rationale for investigating its use in the treatment of patients with celiac disease? (0:15)
- What were the findings in the phase 2 study of ZED1227 in patients with celiac disease and what will the next steps be? (1:01)
Disclosures: Prof. Detlef Schuppan has no personal financial interests in relation to the content of this video interview; however, discloses scientific-clinical activities with research support from Zedira, Falk Pharma, Topas Therapeutics, Calypso and DFG.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
